Among this receptor family, SIGLEC5 and its soluble form, soluble SIGLEC5 (sSIGLEC5), have been shown to bind the highly sialylated P-selectin glycoprotein ligand-1 (PSGL-1) molecule present on T lymphocytes, promoting tumour progression [22,23]. Here, SIGLEC5 is linked to neoplasm.